We describe a new PCR test (Penter RT-PCR) that recognizes all 64 prototypes of enterovirus. Sixty clinical samples were analyzed in parallel with this Penter RT-PCR and previously described PCR tests: 34 and 32 samples tested positive, respectively. This assay is suitable for use in clinical diagnosis, and its ability to amplify all known serotypes makes it more useful than other consensus PCR tests.Enteroviruses (EVs) are small single-stranded RNA viruses that comprise 64 serotypes recently redistributed into five species (22). They are responsible for a wide variety of clinical manifestations (eruptions and respiratory, ocular, cardiac, and neurological symptoms [8,17]). The PCR test first described almost 10 years ago (3, 9, 18) has become the technique of choice for the diagnosis of these infections, particularly for cerebrospinal fluids (7). The rapidity of diagnosis by PCR has proved to be the determining factor in the management of patients, reducing the cost (by preventing unnecessary use of antibiotics) and duration of hospitalization (15,16). None of the PCR techniques proposed to date, using primers located in the 5Ј noncoding region, recognizes all 64 prototypes of EVs. The primers described by Zoll et al. do not amplify coxsackieviruses A11, A17, A24 or echovirus 16 (23). Furthermore, it is known that EVs exhibit a high degree of intratypic sequence heterogeneity (13). We describe a new PCR method (Penter RT-PCR) that detects all serotypes of EVs.The Penter RT-PCR primers (Penter-1 and 2) were selected from within the 5Ј noncoding region of the EV genome and are 85% identical to known enteroviral RNA sequences. A stair primer PCR system (5, 12) was used. A 420-bp fragment was amplified. This new reverse transcription (RT)-PCR test was performed with all prototypes of EV (obtained from tissue culture or suckling mouse brain), with serotyped field strains, and with frozen clinical samples. These samples were also analyzed by PCR (a technique hereafter referred to as inhouse reference RT-PCR) with primers previously described by Zoll et al. (23) or by Rotbart et al. (19) and by means of the protocols described below.RNA was extracted from prototypes of EV with guanidinium thiocyanate (4, 11). For specimens from patients, RNA was isolated from 140 l of the sample, by using a viral RNA minikit (Qiagen, Courtaboeuf, France) according to the manufacturer's instructions. RNA from a single extraction was used for both PCR tests, and an aliquot (10 l) of RNA extract was used as a template for RT. The reaction was performed in a final volume of 20 l, and we added 10 l of cDNA to 40 l of reaction mixture for all PCR tests. RNA extraction and RT, cDNA amplification, and amplicon detection were performed in three separate, nonadjacent rooms.For the Penter RT-PCR test, the protocol was as follows: RT was performed with 0.5 M Penter-2, 250 M concentrations (each) of the four deoxynucleoside triphosphates (dNTPs), 50 U of Moloney murine leukemia virus reverse transcriptase (Stratagene, Ozyme, Montigny-le-Bretonne...